Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mgG2 EXCT4
- Development stage
- Preclinical
- Lead developer
- Simplexia
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
mgG2 EXCT4 (also known as gG2 EXCT4 or SIM-2) is a preclinical-stage recombinant protein subunit vaccine being developed by Simplexia for the prevention and treatment of genital herpes caused by herpes simplex virus type 2 (HSV-2), as well as associated complications such as neonatal herpes and recurrent (Mollaret's) meningitis. The vaccine candidate consists of a soluble recombinant variant of the normally membrane-bound region of HSV-2 glycoprotein G-2 (mgG-2), designated EXCT4. Unlike other HSV-2 glycoproteins, mgG-2 has low sequence homology with its HSV-1 counterpart, allowing it to induce an HSV-2 type-specific immune response without interference from prior HSV-1 infections. Preclinical studies in mouse models have demonstrated that mgG2 EXCT4 provides robust protection against genital HSV-2 infection and neurological disease.
- Other names
- gG2-EXCT4gG-2-EXCT4gG 2-EXCT4glycoprotein G-2 vaccinemgG-2 vaccinemgG2 vaccinemgG 2 vaccinemgG2-EXCT4mgG-2-EXCT4mgG 2-EXCT4soluble recombinant glycoprotein G-2 vaccine
Beyond the preview
Go deeper on mgG2 EXCT4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mgG2 EXCT4.